Novel Mechanisms of Calcium Signaling in B lymphocytes
Novel Mechanisms of Calcium Signaling in B lymphocytes
批准号:
8417768
负责人:
BRUCE D FREEDMAN
金额:
$37.22万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-02-01 至 2015-01-31
关键词:
Adaptor Signaling ProteinAntibodiesAntigen ReceptorsAutoimmune ProcessB-LymphocytesBLNK geneBindingCalciumCalcium SignalingCationsCell membraneClinicCouplingCytoplasmCytoskeletonDataDevelopmentDiseaseDistalEndoplasmic ReticulumGenerationsImmuneImmune System DiseasesImmune responseImmunologic Deficiency SyndromesInflammatoryLinkLipaseLymphocyteLymphocyte FunctionMediatingMembraneMicroinjectionsMolecularPathway interactionsPhosphorylationPhosphotransferasesPlayPoint MutationProtein Tyrosine KinaseProteinsRegulationRoleSTIM1 geneSecond Messenger SystemsSignal TransductionStructureSuggestionT-Cell ActivationTRPC3 ion channelTestingTyrosineWorkbaseinhibitor/antagonistinsightnovelpublic health relevancereceptorsecond messengersensor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Calcium (Ca2+) is a multifunctional second messenger that regulates lymphocyte differentiation and function. The pathways that initiate Ca2+signaling following antigen receptor engagement in lymphocytes are well delineated. For example, antigen receptor engagement on B cells, activates tyrosine kinases Lyn/Syk and the consequent activation of PLC32 results in the generation of IP3, which activates channels (IP3 receptors) on the endoplasmic reticulum (ER) membrane. Depletion of IP3-sensitive ER Ca2+ stores triggers relocalization of STIM1, the ER Ca2+ sensor, into punctate structures in junctional ER adjacent to the plasma membrane. Orai1, the recently identified CRAC channel pore located in the plasma membrane, also aggregates into puncta following activation, and its subsequent interaction with STIM1 results in "store-operated" CRAC channel activation. While it has long been thought that IP3-mediated store depletion is both necessary and sufficient for maximal CRAC activation, recent data, including our own data, clearly challenge this notion. Regulation of CRAC activation downstream of IP3-mediated store release was observed in lyn-/-syk-/- B cells following ER Ca2+stores depletion. In support of this idea, our studies demonstrate that CRAC activation is abrogated by either Lyn/Syk inhibitors or neutralizing anti-Lyn and -Syk antibodies introduced into the cytoplasm of single B cells. Our subsequent observation that Orai1 and Syk physically interact led us to hypothesize that Syk is involved in Orai1 redistribution required for CRAC activation. Accordingly, this proposal focuses on the role of Lyn and Syk in the regulation of post-store coupling (Aim1). Another indication that CRAC activity could be independently regulated is provided by our preliminary data that PLC32 directly interacts with Orai1, suggesting. Our data suggest that physical association of PLC32 and Orai1 is critical for CRAC activation and that such interactions can be inhibited by tyrosine phosphorylated TFII-I, a known Btk target. Based on these data and an analogous role for TFII-I in regulating PLC31-dependent activation of TRPC3 Ca2+ channels, we hypothesize that PLC3-2 regulates CRAC channel mediated Ca2+ entry in a lipase-independent manner that is negatively regulated by Btk dependent phosphorylation of TFII-I (tested in Aim 2). Finally, our recent work with Dan Billadeau demonstrates that the adaptor protein WAVE2 regulates Ca2+ entry, but not Ca2+ release from stores following T cell activation. Our preliminary results demonstrate that WAVE2 plays an analogous role in B cells. Furthermore, WAVE2 associates with STIM1 in B cells and dissociates following activation, suggesting a role in orienting STIM1 for interactions with Orai1. We will further explore the mechanistic role of WAVE2 in BCR-induced CRAC activation in Aim 3. Tight regulation of Ca2+signaling is critical for lymphocyte effector function and its dysregulation contributes to immunodeficiency as well as inflammatory diseases. Our proposed studies will identify additional mechanisms by which Ca2+ signaling could go awry in disease states. Results from these studies will also provide insight into approaches to ameliorate immunodeficiency diseases and/or autoimmune and inflammatory conditions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Oncolytic virus targeting Schistosomes
-
批准号:10372084
-
项目类别:
-
资助金额:$20.31万
-
财政年份:2021
-
负责人:BRUCE D FREEDMAN
-
依托单位:
Calcium Regulation of NF-kB Activation in Lymphocytes
-
批准号:9352513
-
项目类别:
-
资助金额:$57.6万
-
财政年份:2016
-
负责人:BRUCE D FREEDMAN
-
依托单位:
Building Enhanced Capability for the PennVet Multiphoton Core
-
批准号:9075603
-
项目类别:
-
资助金额:$60.0万
-
财政年份:2016
-
负责人:BRUCE D FREEDMAN
-
依托单位:
FLIM system, resonant scanner, and UV laser for 2 photon microscope
-
批准号:7794472
-
项目类别:
-
资助金额:$49.63万
-
财政年份:2010
-
负责人:BRUCE D FREEDMAN
-
依托单位:
Novel mechanisms of Ca2+ signaling in B lymphocytes
-
批准号:6923251
-
项目类别:
-
资助金额:$39.63万
-
财政年份:2005
-
负责人:BRUCE D FREEDMAN
-
依托单位:
Novel mechanisms of Ca2+ signaling in B lymphocytes
-
批准号:7339631
-
项目类别:
-
资助金额:$36.86万
-
财政年份:2005
-
负责人:BRUCE D FREEDMAN
-
依托单位:
Novel Mechanisms of Calcium Signaling in B lymphocytes
-
批准号:8605495
-
项目类别:
-
资助金额:$39.6万
-
财政年份:2005
-
负责人:BRUCE D FREEDMAN
-
依托单位:
Novel Mechanisms of Calcium Signaling in B lymphocytes
-
批准号:8211059
-
项目类别:
-
资助金额:$39.6万
-
财政年份:2005
-
负责人:BRUCE D FREEDMAN
-
依托单位:
Novel Mechanisms of Calcium Signaling in B lymphocytes
-
批准号:7887578
-
项目类别:
-
资助金额:$39.9万
-
财政年份:2005
-
负责人:BRUCE D FREEDMAN
-
依托单位:
Novel mechanisms of Ca2+ signaling in B lymphocytes
-
批准号:7172920
-
项目类别:
-
资助金额:$37.57万
-
财政年份:2005
-
负责人:BRUCE D FREEDMAN
-
依托单位:
Novel Mechanisms of Calcium Signaling in B lymphocytes
-
批准号:8012265
-
项目类别:
-
资助金额:$39.6万
-
财政年份:2005
-
负责人:BRUCE D FREEDMAN
-
依托单位:
Novel mechanisms of Ca2+ signaling in B lymphocytes
-
批准号:7552021
-
项目类别:
-
资助金额:$36.86万
-
财政年份:2005
-
负责人:BRUCE D FREEDMAN
-
依托单位:
Novel mechanisms of Ca2+ signaling in B lymphocytes
-
批准号:7008181
-
项目类别:
-
资助金额:$38.69万
-
财政年份:2005
-
负责人:BRUCE D FREEDMAN
-
依托单位:
HIV ENV & MACROPHAGE CHEMOKINE RECEPTOR IONIC SIGNALING
-
批准号:6748995
-
项目类别:
-
资助金额:$27.74万
-
财政年份:2001
-
负责人:BRUCE D FREEDMAN
-
依托单位:
HIV ENV & MACROPHAGE CHEMOKINE RECEPTOR IONIC SIGNALING
-
批准号:6511435
-
项目类别:
-
资助金额:$27.74万
-
财政年份:2001
-
负责人:BRUCE D FREEDMAN
-
依托单位:
HIV ENV & MACROPHAGE CHEMOKINE RECEPTOR IONIC SIGNALING
-
批准号:6312479
-
项目类别:
-
资助金额:$27.74万
-
财政年份:2001
-
负责人:BRUCE D FREEDMAN
-
依托单位:
HIV ENV & MACROPHAGE CHEMOKINE RECEPTOR IONIC SIGNALING
-
批准号:6632384
-
项目类别:
-
资助金额:$27.74万
-
财政年份:2001
-
负责人:BRUCE D FREEDMAN
-
依托单位:
IONIC CONDUCTANCES AND CD4 LYMPHOCYTE DIFFERENTIATION
-
批准号:6373525
-
项目类别:
-
资助金额:$22.04万
-
财政年份:1997
-
负责人:BRUCE D FREEDMAN
-
依托单位:
IONIC CONDUCTANCES AND CD4 LYMPHOCYTE DIFFERENTIATION
-
批准号:6169741
-
项目类别:
-
资助金额:$21.4万
-
财政年份:1997
-
负责人:BRUCE D FREEDMAN
-
依托单位:
IONIC CONDUCTANCES AND CD4 LYMPHOCYTE DIFFERENTIATION
-
批准号:2672750
-
项目类别:
-
资助金额:$20.23万
-
财政年份:1997
-
负责人:BRUCE D FREEDMAN
-
依托单位:
海外基金